Cargando…

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia

Despite recent relevant therapeutic progresses, chronic lymphocytic leukemia (CLL) remains an incurable disease. Selinexor, an oral inhibitor of the nuclear export protein XPO1, is active as single agent in different hematologic malignancies, including CLL. The purpose of this study was to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitale, Candida, Griggio, Valentina, Todaro, Maria, Riganti, Chiara, Jones, Rebecca, Boccellato, Elia, Perutelli, Francesca, Arruga, Francesca, Vaisitti, Tiziana, Efremov, Dimitar G., Deaglio, Silvia, Landesman, Yosef, Bruno, Benedetto, Coscia, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560255/ https://www.ncbi.nlm.nih.gov/pubmed/37805613 http://dx.doi.org/10.1038/s41598-023-44039-0

Ejemplares similares

Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
por: Griggio, Valentina, et al.
Publicado: (2020)

Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia
por: Vitale, Candida, et al.
Publicado: (2021)

Targeting HIF-1α Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL
por: Vitale, Candida, et al.
Publicado: (2021)

CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?
por: Vitale, Candida, et al.
Publicado: (2023)

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
por: Perutelli, Francesca, et al.
Publicado: (2022)

Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?
por: Vaisitti, Tiziana, et al.
Publicado: (2018)

Targeting the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia
por: Arruga, Francesca, et al.
Publicado: (2020)

Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions
por: Arruga, Francesca, et al.
Publicado: (2020)

The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies
por: Arruga, Francesca, et al.
Publicado: (2018)

Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs
por: Vitale, Candida, et al.
Publicado: (2020)

Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets
por: Vaisitti, Tiziana, et al.
Publicado: (2019)

Chronic Lymphocytic Leukemia
por: Vaisitti, Tiziana, et al.
Publicado: (2020)

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
por: Audrito, Valentina, et al.
Publicado: (2020)

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor
por: Vaisitti, Tiziana, et al.
Publicado: (2017)

CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia
por: D’Arena, Giovanni, et al.
Publicado: (2021)

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
por: Arruga, Francesca, et al.
Publicado: (2023)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia
por: Dogliotti, Irene, et al.
Publicado: (2021)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

The Nuclear Export Inhibitor Selinexor Inhibits Hypoxia Signaling Pathways And 3D Spheroid Growth Of Cancer Cells
por: Depping, Reinhard, et al.
Publicado: (2019)

Novel Approaches for the Treatment of Patients with Richter’s Syndrome
por: Iannello, Andrea, et al.
Publicado: (2022)

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose
por: Crochiere, Marsha L., et al.
Publicado: (2017)

Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor
por: Marcus, Joshua M., et al.
Publicado: (2015)

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
por: D’Arena, Giovanni, et al.
Publicado: (2020)

Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity
por: von Fallois, Moritz, et al.
Publicado: (2021)

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
por: Kashyap, Trinayan, et al.
Publicado: (2018)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia
por: Griggio, Valentina, et al.
Publicado: (2016)

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
por: Fisher, Jack G., et al.
Publicado: (2021)

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms
por: Walker, Christopher J., et al.
Publicado: (2022)

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer
por: Martini, Silvia, et al.
Publicado: (2021)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
por: Griggio, Valentina, et al.
Publicado: (2020)

421 A Phase 1 and Randomized Phase 2 Clinical Trial of Selinexor and Temozolomide in Recurrent Glioblastoma Among Adults: The Product of a Successful Team Science Approach
por: Chow, Frances, et al.
Publicado: (2023)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
por: Baek, Han Bit, et al.
Publicado: (2018)

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
por: Kashyap, Trinayan, et al.
Publicado: (2021)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
por: Cass, Michael, et al.
Publicado: (2022)

Selinexor for multiple myeloma
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n4aou0nt2js9h5m72sk0boo47q